ASC to Present Unique Technology at Antibody Engineering & Therapeutics 2020 | ASC

Milpitas, CA – August 11th, 2020: Applied StemCell is excited to be a part of the Antibody Engineering & Therapeutics (Virtual Event) 2020. Come and share with us about our new technology for mammalian cell library screening, and to see how this technology can advance your antibody engineering and screening applications.

Presentation Title: TARGATT™: Rapid Site-Specific Gene Integration Technology Stable Cell Lines for Bioproduction and Mammalian Cell-Based Library Screening

Presenter: Ruby Tsai, PHD

Poster Presentation Title: Mammalian Cell Display System: Construction of a Naïve Library by Insertion of Human Immunoglobulin Germline Sequences Using TARGATT™ Technology

Authors: Xiuling Chi*, Alfonso Farruggio, Iris Lin, and Ruby Yanru Chen-Tsai. Applied StemCell, Inc.

Presenter: Xiuling Chi, PhD

Come and visit https://informaconnect.com/antibody-engineering-therapeutics/sponsors/applied-stemcell/. It will be a great opportunity to meet with ASC’s experts. Also please send inquiries to info@appliedstemcell.com for the presentation and poster published at Antibody Engineering & Therapeutics (Virtual Event) 2020.

EVENT DETAILS

Date: December 14-16, 2020

Event URL: https://informaconnect.com/antibody-engineering-therapeutics/agenda/7/

About Applied StemCell, Inc.

Applied StemCell, Inc. (ASC) is a fast-growing Gene & Cell Therapy CRO headquartered in California, USA. ASC was founded in 2008 with a goal to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry. With more than 12 years of experience in genome editing and stem cell technologies, ASC is proud to develop innovative technology platforms offering services and products in the field of Stem Cells (iPSCs/ESCs, differentiated cells) and animal/cell models for disease modeling, antibody discovery & screening, bioproduction, AAV potency assays, cell therapy and regenerative medicine. Our Cell and Gene Therapy Bioservice platform also includes consultation for Pre-IND filing and CMC processes.

More information can be found at www.appliedstemcell.com.

Media Contact:

Maki Ogawa

Marketing Director, Applied StemCell, Inc.

408-773-8007

maki.ogawa@appliedstemcell.com